Results 141 to 150 of about 25,647 (343)
Four Hour Temporal Relation of 5-HTP and L-DOPA Induces Inhibitory Responses in Recrudescing Gonad of Indian Palm Squirrel (Funambulus pennantii) [PDF]
C. M. Chaturvedi, Ranjana Jaiwal
core +1 more source
Refractory Motor Complications: Towards a Pragmatic Definition
Movement Disorders Clinical Practice, EarlyView.
Georg Ebersbach, Tobias Warnecke
wiley +1 more source
Abstract Background Neuroinflammation, measured using [11C](R)‐PK11195 positron emission tomography (PET), has been reported in isolated rapid‐eye‐movement sleep behavior disorder (iRBD), but its temporal progression is unknown. Objective The aim was to assess longitudinal progression of neuroinflammation in iRBD patients and its relationship with ...
Andreas Myhre Baun +17 more
wiley +1 more source
D2 receptor ablation in indirect‐pathway striatal neurons reduces or abolishes dyskinetic and dystonic behaviors induced by L‐DOPA or D2 receptor agonists, respectively. Contralateral turning is reduced, while forward locomotion is increased. These effects are associated with modulation of neuronal activity in dorsal striatum and external globus ...
Laura Andreoli +5 more
wiley +1 more source
POLG‐Related Parkinsonism with Good Response to Deep Brain Stimulation
Movement Disorders Clinical Practice, EarlyView.
Evdokia Efthymiou +4 more
wiley +1 more source
Abstract Deep brain stimulation (DBS) effectively treats motor symptoms in movement disorders but often compromises speech through incompletely defined mechanisms. We conducted a PROSPERO‐registered systematic review and meta‐analysis of publications through August 2024 (CRD42024527738).
Elina Tripoliti +15 more
wiley +1 more source
Distant precursors of benzylisoquinoline alkaloids and their enzymatic formation [PDF]
Rüffer, Martina, Zenk, Meinhart H.
core +1 more source
Levodopa Efficacy and GLP‐1 Receptor Agonists
Movement Disorders Clinical Practice, EarlyView.
Catherine Martinez +3 more
wiley +1 more source
ABSTRACT Background Dopa‐responsive dystonia is caused by pathogenic variants in the GCH1 gene. Although its clinical features and reduced penetrance are known, in vivo metabolic and structural alterations in symptomatic (sMC) and asymptomatic mutation carriers (aMC) remain poorly understood.
Jannik Prasuhn +12 more
wiley +1 more source
THE METABOLISM OF 3,4-DIHYDROXYPHENYLALANINE
K N, SHAW, A, MCMILLAN, M D, ARMSTRONG
openaire +2 more sources

